Abstract: Fibrin glue is a two-component adhesive used to stop bleeding, seal wound edges and for scaffolds in tissue engineering. Autologous products result in reduced risk of contamination and immunological responses compared to commercially available fibrin glue. However, reproducibility due to patient dependent sealant properties of autologous fibrin glue preparation is low. In this study a fully automated production process for both the fibrinogen and thrombin component from small blood volumes was developed. The resulting fibrinogen concentration, thrombin activity and sealant properties of the fibrin glue were determined. The fully automated and closed production system proved to be a promising tool for fast and easy production of autologous fibrin glue with an effective adhesive quality.
Introduction
Fibrin glue is a two-component adhesive of fibrinogen and thrombin based on imitating the coagulation process of the body. By combining the thrombin and fibrinogen component conversion of fibrinogen to fibrin takes place and a clot is formed by a three-dimensional fibrin network [4] . Fibrin glue is used to stop bleeding, seal wound edges with reduced scarring and for scaffolds in tissue engineering [8] . Fibrin glue is commercially available with homologous and xenogenic components or can be produced in an autologous approach from patient blood samples [2, 4] . Using autologous sealants offers the advantages of point of care preparation, reduced risk of contamination and immunological responses, as well as economic factors when compared with commercially available, ready to use fibrin glues [2, 4] . Disadvantages of patient derived fibrin glue preparations are found in low reproducibility due to variations between individuals [9] .
The adhesive quality of fibrin glue correlates with the polymerisation process of the fibrinogen-thrombin mixtures and depends on the thrombin activity and fibrinogen concentration [6] . In commercial sealants the thrombin activity has been reported at 4-1000 IU/ml [4, 5] and the fibrinogen concentration at 19.88 mg/ml, 35-55 mg/ml and 80-100 mg/ml [4] [5] [6] .
In autologous approaches the fibrinogen component is concentrated from whole blood with plasma fibrinogen levels of 2-6 mg/ml [9] of which up to 100 % can be recovered by an optimized precipitation method [1] . Commonly used methods are cryoprecipitation reaching concentrations of 20-40 mg/ml or precipitation with chemical agents for values > 50 mg/ml [1] . The devices Vivostat® and CryoSeal® are used for autologous preparation of fibrin glue [4] . With Vivostat® 4.77 ml of fibrin are generated from 120 ml of whole blood [9] resulting in a fibrinogen concentration of 18.69 mg/ml [4] . With CryoSeal® 11.7 ± 5 ml of fibrinogen and 8 ± 1 ml of thrombin are produced from 450 ml of plasma resulting in a fibrinogen concentration of 22.1 ± 7.5 mg/ml and a thrombin activity of 38 ± 20 U/ml [3] .
The adhesive properties of fibrin glue preparations are used to classify the products and are often evaluated via tensile testing [1, [5] [6] [7] . Tensile testing of fibrin glue has been reported using vital human tissue [6] , rat or pig skin and canine or rat models [7] . The adhesive strength of commercial sealants tested in animal models was reported at 0.0242-0.0775 mN/cm 2 with maximum forces of 300-1000 mN [7] . Testing with human tissue reached an adhesive strength of 811.1 mN/cm 2 [6] using commercial fibrin sealant and 531.2 mN/cm 2 using the autologous Vivostat® System [6] . An autologous fibrinogen preparation combined with bovine thrombin (500 U/ml) resulted in adhesive strengths of 450-600 mN/cm 2 [1] .
In this study a new device for fully automated production of both the autologous thrombin and fibrinogen component from small blood volumes was developed and the resulting component and sealant quality was evaluated.
Methods

Processing and evaluation of thrombin and fibrinogen
Blood processing was performed with a standard laboratory centrifuge (Rotanta 460, Andreas Hettich GmbH Co KG; Tuttlingen, Germany) equipped with a specially designed rotor for automated production of autologous blood derivatives. All photometric measurements were performed with a microplate photometer (Multiskan FC, Thermo Fisher Scientific, Waltham, MA, USA).
Thrombin
For thrombin production, venous blood was drawn from healthy donors with 12 ml syringes prefilled with 36 glass beads (ø 4 mm, borosilicate glass, Schäfer Glas GmbH, Kaufbeuren, Germany). The filled syringes (10 ml blood, 36 glass beads) were dynamically incubated for 20 min resulting in thrombin and fibrin generation due to coagulation. Empty syringes of equal size were connected to the incubated syringes with a hose and inserted into the rotor (see Figure   1 ). The connected syringe pairs were centrifuged at 930 g for 20 min resulting in separation of serum containing the thrombin from the cellular and fibrin clot components. The thrombin component was then automatically transferred into syringe B.
To assess the amount of thrombin contained in the produced serum (thrombin component) 150 µl were mixed with 50 µl of the chromogenic substrate S-2238 TM (Chromogenix, Instrumentation Laboratory, Bedford, MA, USA) at 3 mmol/l and incubated at 37 °C for 20 min. Photometric measurements were performed immediately at 405 nm and 540 nm and compared to measurements with human plasma thrombin (605190-100 U, Merck Millipore Corp., Billerica, USA) of known concentration (1,25 U/ml).
Fibrinogen
For fibrinogen production, venous blood was drawn from healthy donors with 12 ml syringes prefilled with 1 ml of citrate (4 % sodium citrate, Duomedica GmbH, Maintal, Germany). The filled syringes (11 ml blood, 1 ml citrate) were connected to syringes of equal size prefilled with 1.2 ml of ethanol (absolute for analysis, Merck KGaA, Darmstadt, Germany) and set into the automated centrifugation system (see Figure 2) .
In the first centrifugation step at 930 g for 5 minutes, platelet rich plasma (PRP) or for 20 minutes, platelet poor plasma (PPP), respectively, was generated in syringe A. Plasma was then transferred into syringe B and mixed with the prefilled ethanol. The following cooled centrifugation step at 1 °C and 1100-2100 g for 20-30 minutes resulted in precipitation of fibrinogen. The supernatant was transferred back into syringe A resulting in the fibrinogen component at an adjustable volume in syringe B.
By removing all remaining plasma supernatant and using a precision scale (CP423S, Sartorius AG, Göttingen, Germany) the fibrinogen amount was assessed. A turbidimetric method as described in [9] was used for measurement of the fibrinogen concentration. 50 µl of the produced fibrinogen were mixed with 2 ml of fibrinogen reagent (116 g/l ammonium sulphate, 1.4 g/l guanidine hydrochloride, 9 g/l EDTA, deionized water, pH value 4.9). Photometric measurements were performed after 120 sec at 405 nm and compared to measurements with human plasma fibrinogen (341576-100MG, Merck Millipore Corp., Billerica, MA, USA) of known concentration (25 mg/ml).
Adhesive quality
The sealant quality was determined by mixing the thrombin and fibrinogen component at equal volumes and evaluating the clotting properties via time of clot formation, size of the formed clot and adhesive strength. 100 µl of the thrombin component were mixed with 100 µl of the fibrinogen component and photometric measurements were performed every 5 sec for 15 min at 405 nm. The time until the maximum turbidity was reached was defined as the time of clot formation. Following the 15 min measurement the stabilized clots were weighed with a precision scale and the clotting percentage was calculated.
Adhesion experiments were performed with a tensile testing machine (Z2.5TN, Zwick GmbH & Co KG, Ulm, Germany) using a 10 N load cell (KAP-TC, Angewandte System-Technik GmbH, Dresden, Germany) and 3d printed test pieces covered with a fleece membrane. 50 µl of fibrinogen and 50 µl of thrombin were mixed and transferred onto the bottom test piece covering a surface of 1.57 cm 2 (see Figure 3a) . After a curing time of 15 min the upper test piece was applied (see Figure 3b ) for bonding times of 5 to 20 min before straining at 3 mm/min (see Figure 3c ). The adhesive strength was recorded until the fibrin network ruptured.
Results
The quality of the thrombin and fibrinogen component, as well as the sealant properties of the fibrin glue mixture were determined. An overview of the results in comparison to sealants tested in other work is stated in table 1. 
Thrombin
The thrombin component was successfully produced in the automated process and the thrombin activity was measured in a total of 43 samples from 8 donors at 48.6 ± 11.4 U/ml.
Fibrinogen
The amount and concentration of fibrinogen produced by the fully automated process (1 °C, 20-30 min, 1100-2100 g) was determined with a total of 50 samples from 6 donors. The medium value of the fibrinogen amount was 369 ± 64 mg with a concentration of 96.61 ± 23.9 mg/ml correlating with an 80.5 ± 19.9 % recovery of the plasma fibrinogen. The plasma fibrinogen concentration before precipitation was measured for 3 donors at 6.83 ± 1.37 mg/ml. Precipitation from PPP resulted in higher fibrinogen concentrations than from PRP. 
Adhesive quality
Discussion
The thrombin and fibrinogen components were successfully produced with effective sealant properties for all tested donors. The fully automated precipitation of fibrinogen from plasma by using ethanol as a chemical agent resulted in very high concentrations with a small donor dependent range for all tested parameters. For a maximum fibrinogen concentration PPP is recommended as a precursor and cooled centrifugation (1 °C) for 30 min at 1600 g. Comparing the component and adhesive quality of the presented fibrin glue to other autologous products (see table 1) shows that the thrombin activity and especially the fibrinogen concentration are higher, whereas the adhesive strength is lower. The fibrinogen concentration even levels with the stated commercial product and the recovery rate of 80.5 ± 19.9 % of the plasma fibrinogen exceeds the stated 19.9 ± 10.6 % of CryoSeal® [3] greatly. Comparability of the adhesive strength to other work is limited due to large differences in the testing conditions. Also, testing with a larger number of samples needs to be performed to confirm the preliminary tests with only two donors. Using CaCl 2 as an additive could increase the adhesive strength as reported previously [1] .
A further important characteristic of autologous fibrin glue preparation is the required amount of blood. With our system, a very small volume of only 24 ml of whole blood are needed for preparation of 7 ml of fibrin glue. In the Vivostat® System 120 ml result in 5 ml of product [9] and in CryoSeal® FS 450 ml of blood result in 20 ml of product [3] . An additional advantage of our fibrin glue is a high amount of growth factors known to enhance wound healing in addition to the gluing effect. We determined an 80-fold increase of platelet derived growth factors (PDGF) in the thrombin component compared to whole blood.
Conclusion
The presented fully automated, fast and easy production process for autologous fibrin glue is a promising approach for economic, point of care preparation making autologous fibrin glue easily available for clinical use.
